...
首页> 外文期刊>Current stem cell research & therapy >Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients.
【24h】

Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients.

机译:静脉内应用同种异体外周血间充质干细胞:对291位马接受者的安全性评估。

获取原文
获取原文并翻译 | 示例

摘要

It has been reported that mesenchymal stem cells (MSCs) have homing capacities and immunomodulating effects after an intravenous injection. However, transplanting MSCs in murine tail veins can result in pulmonary reactions and even death of the animals. Unfortunately, only a few intravenous MSC transplantations have been reported in large animal species and these were performed in a limited number of individuals. To assess the safety of MSC transplantations, a large study on 291 recipient horses is reported here. MSCs were isolated from the peripheral blood (PB) of a 4-year-old and 6-year-old donor horse after having tested their PB for a wide range of transmittable diseases. The MSC samples from both donor horses were characterized and resuspended in 1ml of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% Dimethyl Sulfoxide (DMSO). After hand-thawing in the field, 291 horses with ages ranging from 3-months to 33-years were directly injected into their jugular vein. 281 horses (97%) received a single injection of a physiological dose of 0.2 x10(6) MSCs, 5 horses (1.7%) were re-injected after approximately 6 weeks (using the same dose and donor cells) and a single superphysiological dose of 10(6) MSCs was administered to 5 horses as well. In total, 176 recipients were injected with MSCs from the 4-year-old donor and 115 recipients received MSCs from the 6-year-old donor. From all the injected horses (n=291) no acute clinical adverse effects were noticed. Apart from one horse that died of colic 7 months after the treatment, no deaths were registered and all the horses were monitored for 1 year after the injection. In conclusion, no adverse effects were noticed in 291 recipients after an intravenous injection of allogenic PBderived MSCs. Nevertheless, further research is warranted in order to verify the immunogenic properties of these cells after allogenic transplantation into various (patho)physiological sites.
机译:据报道,在静脉内注射后,间充质干细胞(MSC)具有归巢能力和免疫调节作用。但是,将MSCs移植到鼠尾静脉中会导致肺部反应,甚至导致动物死亡。不幸的是,在大型动物中仅报道了少数静脉MSC移植,这些移植仅在有限的个体中进行。为了评估MSC移植的安全性,此处报道了对291匹接受接受治疗的马的大型研究。在对PB进行了广泛的可传播疾病测试之后,从4岁和6岁供体马的外周血(PB)中分离了MSC。表征来自两个供体马的MSC样品,并将其重悬于补充有10%二甲基亚砜(DMSO)的1ml Dulbecco改良Eagle培养基(DMEM)中。在野外解冻后,将年龄在3个月至33岁之间的291匹马直接注入颈静脉。 281匹马(97%)接受了生理剂量为0.2 x10(6)MSC的单次注射,约6周(使用相同剂量和供体细胞)和单次超生理剂量后,再次注射了5匹马(​​1.7%) 10(6)个MSC中的5个也被给予了治疗。总共向176位接受者注射了4岁供体的MSC,而115位接受者接受了6岁供体的MSC。在所有注射的马中(n = 291),未观察到急性临床不良反应。除了一匹在治疗后7个月死于绞痛的马之外,没有任何死亡记录,并且在注射后的1年内对所有这些马进行监测。总之,静脉注射同种异体PB来源的MSC后,没有发现291位接受者有不良反应。然而,为了验证这些细胞在同种异体移植到各种(病理)生理部位后的免疫原性,仍需要进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号